<bill session="107" type="h" number="2747" updated="2013-07-14T18:57:56-04:00">
  <state datetime="2001-08-02">REFERRED</state>
  <status>
    <introduced datetime="2001-08-02"/>
  </status>
  <introduced datetime="2001-08-02"/>
  <titles>
    <title as="introduced" type="short">Stem Cell Research for Patient Benefit Act of 2001</title>
    <title as="introduced" type="official">To require implementation of the National Institutes of Health Guidelines for Research Using Human Pluripotent Stem Cells, and for other purposes.</title>
  </titles>
  <sponsor id="400101"/>
  <cosponsors>
    <cosponsor id="400007" joined="2001-10-12"/>
    <cosponsor id="400043" joined="2001-09-06"/>
    <cosponsor id="400047" joined="2001-09-06"/>
    <cosponsor id="400126" joined="2001-09-06"/>
    <cosponsor id="400133" joined="2001-09-06"/>
    <cosponsor id="400140" joined="2001-10-12"/>
    <cosponsor id="400161" joined="2001-09-06"/>
    <cosponsor id="400223" joined="2001-09-06"/>
    <cosponsor id="400230" joined="2001-09-06"/>
    <cosponsor id="400263" joined="2001-09-06"/>
    <cosponsor id="400292" joined="2001-09-06"/>
    <cosponsor id="400332" joined="2001-08-02"/>
    <cosponsor id="400528" joined="2001-10-12"/>
    <cosponsor id="400358" joined="2001-09-06"/>
    <cosponsor id="400509" joined="2001-09-06"/>
  </cosponsors>
  <actions>
    <action state="REFERRED" datetime="2001-08-02">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2001-08-10">
      <text>Referred to the Subcommittee on Health.</text>
      <committee name="House Committee on Energy and Commerce"/>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" activity="Referral, In Committee"/>
    <committee activity="Referral" code="HSIF14" subcommittee="Health" name="House Energy and Commerce"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Administrative procedure"/>
    <term name="Bioethics"/>
    <term name="Cloning"/>
    <term name="Congress"/>
    <term name="Congressional reporting requirements"/>
    <term name="Cytology"/>
    <term name="Department of Health and Human Services"/>
    <term name="Drug therapy"/>
    <term name="Economics and public finance"/>
    <term name="Federal advisory bodies"/>
    <term name="Federal aid to medical research"/>
    <term name="Fetal tissues"/>
    <term name="Genetic research"/>
    <term name="Government operations and politics"/>
    <term name="Human embryology"/>
    <term name="Human genetics"/>
    <term name="Immunosuppressive drugs"/>
    <term name="Law"/>
    <term name="Medical genetics"/>
    <term name="Medical research"/>
    <term name="Research grants"/>
    <term name="Science, technology, communications"/>
    <term name="Transplantation of organs, tissues, etc."/>
  </subjects>
  <amendments/>
  <summary>8/2/2001--Introduced.
Stem Cell Research for Patient Benefit Act 2001 - Requires the Director of the National Institutes of Health to: (1) conduct or support research using human pluripotent stem cells from embryos and fetal tissue in accordance with the National Institutes of Health Guidelines for Research Using Human Pluripotent Stem Cells; and (2) study and report to specified congressional committees on stem cells and the effectiveness of such guidelines.Requires the Secretary of Health and Human Services to enter into an agreement with: (1) the Institute of Medicine under which the Institute shall assess the current state of knowledge about therapies, including somatic cell nuclear transfer and therapies using pharmaceuticals, that may be used to address immunological rejection of stem cells and differentiated cells and tissue derived from stem cells; and (2) another appropriate public or nonprofit private entity to conduct such assessment if the Institute declines.Establishes the Biomedical Advisory Commission to study: (1) bioethical issues arising from research on human biology and applications of such research; and (2) emerging biomedical research, including the ethical, social, legal, and regulatory issues concerning such research and its clinical applications.</summary>
</bill>
